PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 88 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2014. The put-call ratio across all filers is 1.23 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $152,000 | -79.7% | 22,433 | -71.7% | 0.00% | -81.0% |
Q1 2017 | $749,000 | +77.5% | 79,369 | +62.5% | 0.02% | +110.0% |
Q4 2016 | $422,000 | +85.9% | 48,836 | +36.2% | 0.01% | +100.0% |
Q3 2016 | $227,000 | +23.4% | 35,845 | -18.0% | 0.01% | +25.0% |
Q2 2016 | $184,000 | +65.8% | 43,712 | +71.0% | 0.00% | +33.3% |
Q1 2016 | $111,000 | -28.4% | 25,570 | +1.2% | 0.00% | 0.0% |
Q4 2015 | $155,000 | -20.5% | 25,277 | -25.7% | 0.00% | 0.0% |
Q3 2015 | $195,000 | -44.1% | 34,027 | -27.2% | 0.00% | -50.0% |
Q2 2015 | $349,000 | +301.1% | 46,752 | +222.8% | 0.01% | +200.0% |
Q1 2015 | $87,000 | -56.3% | 14,482 | -44.9% | 0.00% | -33.3% |
Q4 2014 | $199,000 | +176.4% | 26,292 | +88.4% | 0.00% | +200.0% |
Q3 2014 | $72,000 | +41.2% | 13,958 | +11.0% | 0.00% | 0.0% |
Q1 2014 | $51,000 | -50.0% | 12,578 | -37.9% | 0.00% | 0.0% |
Q3 2013 | $102,000 | – | 20,267 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
SEARLE & CO. | 60,000 | $349,000 | 0.34% |
TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |